Out-licensing2026
NovaRock × Bionyra
Exclusive license agreement for NBL-023, a novel anti–IL-25 monoclonal antibody, granting worldwide rights outside Greater China.
Lead business development & transaction advisor
Read announcementPDFBIOTECH & BIOPHARMA ADVISORY
Cross-border deals.
Lasting value.
John Adamou helps biotech and biopharma companies find the right partners, structure agreements, and close deals across North America, Europe, and Asia.
Independent perspective. Experienced execution.
JOHN’S CAREER TRACK RECORD
85Partnerships executed
$25B+Total partnership value
Experience connecting science, capital, and partners worldwide.
BUILT ON RELATIONSHIPS. CONNECTED ACROSS CONTINENTS.
North America✳Europe✳Asia
YOUR AMBITION. OUR EXPERTISE.
From possibility
to partnership.
Strategic counsel and hands-on support across the entire business development value chain. The right expertise, exactly where you need it.
01
Strategy & positioning
Build a clear path forward with strategic guidance, deal benchmarking, and a focused view of the opportunity.
02Partnering & outreach
Connect with the right collaborators through a global network and a targeted partnering process.
03Transactions & execution
Move from shared ambition to signed agreement with diligence, deal structuring, and negotiation support.
In-licensing · Out-licensing · Strategic collaborations · Asset acquisitions
Explore all services
EXPERIENCE THAT MOVES THINGS FORWARD
A global outlook.
A personal commitment.
With more than 25 years in biotech and pharma, John brings strategic perspective and transaction experience to every engagement.
From search and evaluation to deal structuring and alliance management, you work directly with an advisor who understands the whole journey.
Meet John25+
Years in healthcare leadership
85
Partnerships executed
$25B+
Total partnership value
SELECTED PARTNERSHIPS
Good relationships.
Meaningful outcomes.
Out-licensing2026
NovaRock × LigaChemBio
Global out-licensing agreement for an ADC candidate targeting a novel oncology antigen.
Lead business development & transaction advisor
Read announcementPDFStrategic partnership2025
CSPC × Radiance Biopharma
$1,240 million strategic partnership for ROR1-ADC (SYS6005).
Lead business development & transaction advisor
Read announcementPDFTHE NEXT OPPORTUNITY
Promising science.
Partnership potential.
Explore available assets in oncology and cardiovascular disease, from small molecules to next-generation antibody-drug conjugates.
Explore partnering opportunitiesOverview decks available on request.
01
HER2 Biparatopic ADC
02Oncology · Antibody-Drug Conjugate
KAT6 Inhibitor
03Oncology · Small Molecule
ENPP1 Inhibitor
Cardiovascular · Small Molecule
Browse by target, modality, and development stage. Confirm current status and availability directly with JEA.
A CLEAR PROCESS. A SHARED PURPOSE.
Progress, by design.
Align on the ambition
Understand your science, portfolio, and commercial priorities. Define what a successful partnership needs to achieve.
Find the right fit
Identify and evaluate prospective partners across North America, Europe, and Asia. Build a focused outreach strategy.
Shape the partnership
Coordinate diligence, benchmark alternatives, and structure terms around shared value and clear responsibilities.
Execute with confidence
Support negotiation and closure, then establish the foundations for a productive alliance.
Who does JEA work with?
Biotech and biopharma companies seeking strategic guidance, in- or out-licensing opportunities, and support across the business development value chain.
Do you support cross-border partnerships?
Yes. JEA specializes in identifying, structuring, negotiating, and executing partnerships across North America, Europe, and Asia.
Can we engage you for one part of a transaction?
Yes. Engagements can cover targeted strategic advice, partner identification, due diligence, deal structuring, negotiation, or the full partnering process.
How are engagements structured?
Hourly, retainer, project-based, and blended models are available. Scope, deliverables, and commercial terms are discussed directly for each engagement.
How can I learn more about an available asset?
Browse the opportunities library and request an overview deck from an asset page. Current availability and development status should be confirmed directly with JEA.
What should I share in an initial inquiry?
Your company, the type of support you need, relevant territories, and your timeline are a useful starting point. Keep the first introduction non-confidential.
THE NEXT CONVERSATION COULD CHANGE EVERYTHING
Great science deserves
the right partnership.
Let’s talk about where you want to go,
and how we can help you get there.